摘要
目的观察多西他赛(Taxotere)和草酸铂(L-OHP)联合化疗双周方案治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的疗效和毒副反应。方法51例NSCLC患者(初治16例,复治35例;ⅢB期19例,Ⅳ期32例)应用化疗方案为多西他赛60mg/m2,静脉滴入,d1、d15;草酸铂100mg/m2,静脉滴入,d1、d15。两周为1个周期,均采用4个周期以上评价疗效及毒副反应。结果51例患者均可评价疗效,共完成358个周期化疗。完全缓解1例,部分缓解18例,总有效率37.3%;其中初治者有效率56.3%,复治者为31.4%;ⅢB期有效率57.9%,Ⅳ期为25.0%。中位缓解期5.6个月,中位生存期11.5个月。主要毒副反应为骨髓抑制和外周神经炎。结论多西他赛联合草酸铂双周化疗方案对晚期NSCLC有较好的疗效和可以耐受的毒副反应。
OBJECTIVE： To observe the therapeutic effect and toxic side-effects of the combination chemotherapy with taxotere and oxaliplatin biweekly in the treatment of non-small cell lung cancer （NSCLC）. METHODS, There were totally 51 NSCLC patients （primary treatment for 16 cases, return treatment for 35 cases, 19 cases of stage Ⅲ b and 32 cases of stage Ⅳ）. TP chemotherapeutic regimen： taxotere 60 mg/m^2 d1 , d15, oxaliplatin 100 mg/m^2 , d1 , d15, all used by intravenous injection, repeated every 2 weeks. The evaluation time of therapeutic effect and side-effects was more than 4 cycles. RESULTS：Fifty-one cases were evaluable, and totally finished 358 cycles. Complete response was observed in 1 patient and partial response was observed in 18 patients, the overall response rate was 37.3%. The response rate of the primary treatment patients was 56.3% ,and the return treatment 31.4%, the cases of stage Ⅲ b being 57, 9%, and stage Ⅳ 25. 0%. The median response duration was 5.6 months and the median survival period was 11.5 months. The principle toxic side-effects were inhibition of bone marrow and peripheral neuritis. CONCLUSIONS： TP regimen biweekly in the treatment of advanced non-small cell lung cancer shows a better therapeutic effect, and its toxic side-effects are tolerant.
出处
《中华肿瘤防治杂志》
CAS
2006年第22期1744-1746,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺/药物疗法
抗肿瘤联合化疗方案/治疗应用
治疗结果
carcinoma, non-small cell lung/drug therapy
antineoplastic combined chemotherapy protocols/therapu-tic uses
treatment outcome
